Comparison of Prostate-Specific Promoters and the Use of PSP-Driven Virotherapy for Prostate CancerReport as inadecuate

Comparison of Prostate-Specific Promoters and the Use of PSP-Driven Virotherapy for Prostate Cancer - Download this document for free, or read online. Document in PDF available to download.

BioMed Research InternationalVolume 2013 2013, Article ID 624632, 15 pages

Research Article

Department of Pathology and Laboratory Medicine, The University of Tennessee Health Science Center, Cancer Research Building, Room 218, 19 South Manassas Street, Memphis, TN 38163, USA

Department of Urology, University of Tennessee Health Science Center, Memphis, TN 38163, USA

Received 12 October 2012; Accepted 19 December 2012

Academic Editor: Changqing Su

Copyright © 2013 Yi Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in vivo. To overcome this obstacle, conditional oncolytic viruses such as conditional replication adenovirus CRAD are developed to specifically target prostate without or with minimal systemic toxicity due to viral self-replication. In this study, we have analyzed and compared three prostate-specific promoters PSA, probasin, and MMTV LTR for their specificity and activity both in vitro and in vivo. Both mice model with xenograft prostate tumor model and canine model were used. The best PSP was selected to construct a prostate-specific oncolytic adenovirus CRAD by controlling the adenoviral E1 region. The efficacy and specificity of CRAD on prostate cancer cells were examined in cell culture and animal models.

Author: Yi Lu, Yu Zhang, Guimin Chang, and Jun Zhang



Related documents